Shares of corona vaccine pioneer BioNTech are rebounding somewhat after falling prices in recent trading days.
After falling more than a quarter recently due to cut sales by rival Moderna and the prospect of getting an effective corona pill from Pfizer in major New York trading, BioNTech shares traded 11,98% in the US on the NASDAQ on Monday. high at a close of $ 242,60. The Mainz-based company will publish its quarterly figures these days.
Experts consider the latest setback to be an exaggeration. “Even if re-stocking clean vaccines is not currently in vogue: there is no panic selling either,” stock letter writer Hans Bernecker said Monday. So far, new drugs to reduce the course of the disease have not changed the fact that the need for vaccination is still being promoted. Olga Smolentseva, an analyst at Bryan Garnier, who suspects vaccinations will not be interrupted, sees it in a similar way. According to the expert, at the moment, vaccination remains the most effective method of containing the spread of the virus.
BioNTech after falling prices: stocks in positive territory at the beginning of the week
BioNTech shares were able to recover somewhat on Monday morning after falling sharply the previous week. The share on the Tradegate trading platform increased by 5,6 percent to 201,30 euros.
On Friday, news that Pfizer has an effective coronavirus pill put tremendous pressure on vaccine supplies. The pill from the pharmaceutical company is said to reduce the risk of hospitalization or death by 89 percent. The approval should now be sent.
Investors feared that coronavirus vaccines may now be in much less demand. Vaccinations are likely to remain the most important component of nationwide corona campaigns. In particular, revaccinations can play an important role.
From about the seventh, eighth or ninth month, antibody levels drop after being vaccinated with the BioNTech / Pfizer vaccine. Then there could be a coronavirus infection. “We also observe that when infected, the disease progresses in vaccinated people, usually moderately, and severe progression is rare,” says BioNTech boss Ugur Sahin. “And we have research data that shows that booster vaccinations restore protection against vaccinations. This also applies to the Delta option.
Today, when BioNTech presents data for the third quarter, there may be a prospect for further business development. However, in the long term, the focus is on further development - in particular, oncology projects. Technically speaking, BioNTech stock was recently able to defend the 200-day line. It continues to act as an important support. The shareholder clearly remains confident in the long term.
